Navigation Links
Leading Ebola researcher at UTMB says there's an effective treatment for Ebola
Date:8/29/2014

A leading U.S. Ebola researcher from the University of Texas Medical Branch at Galveston has gone on record stating that a blend of three monoclonal antibodies can completely protect monkeys against a lethal dose of Ebola virus up to 5 days after infection, at a time when the disease is severe.

Thomas Geisbert, professor of microbiology and immunology, has written an editorial for Nature discussing advances in Ebola treatment research. The filoviruses known as Ebola virus and Marburg virus are among the most deadly of pathogens, with fatality rates of up to 90 percent.

Since the discovery of Ebola in 1976, researchers have been actively working on treatments to combat infection. Studies over the past decade have uncovered three treatments that offer partial protection for monkeys against Ebola when given within an hour of virus exposure. One of these treatments, a VSV-based vaccine was used in 2009 to treat a laboratory worker in Germany shortly after she was accidentally stuck with a needle possibly contaminated by an Ebola-infected animal.

Further advances have been made that can completely protect monkeys against Ebola using small 'interfering' RNAs and various combinations of antibodies. But these treatments need to be given within two days of Ebola exposure.

"So although these approaches are highly important and can be used to treat known exposures, the need for treatments that can protect at later times after infection was paramount," said Geisbert.

Further research led to a cocktail of monoclonal antibodies that protected 43% of monkeys when given as late as five days after Ebola exposure, at a time when the clinical signs of the disease are showing.

The new study from Qui and colleagues at MAPP Biopharmaceutical Inc. used ZMAPP to treat monkeys given a lethal dose of Ebola. All of the animals survived and did not show any evidence of the virus in their systems 21 days after infection, even after receiving the treatment 5 days after infection. They also showed that ZMAPP inhibits replication of the Ebola virus in cell culture.

ZMAPP has been used to treat several patients on compassionate grounds. Of these, two US healthcare workers have recovered, although but whether ZMAPP had any effect is unknown, as 45% of patients in this outbreak survive without treatment. There were also two patients treated with ZMAPP who did not survive, but this may be because the treatment was started too late in the disease course.

"The diversity of strains and species of the Ebola and Marburg filoviruses is an obstacle for all candidate treatments," said Geisbert. "Treatments that may protect against one species of Ebola will probably not protect against a different species of the virus, and may not protect against a different strain within the species."

Although we certainly need treatments for filovirus infections, the most effective way to manage and control future outbreaks might be through vaccines, some of which have been designed to protect against multiple species and strains. During outbreaks, single-injection vaccines are needed to ensure rapid use and protection. At least five preventative vaccines have been reported to completely protect monkeys against Ebola and Marburg infection. But only the VSV-based vaccines have been shown to complete protect monkeys against Ebola after a single injection.

"Antibody therapies and several other strategies should be included in the arsenal of interventions for controlling future Ebola outbreaks," said Geisbert. "Although ZMAPP in particular has been administered for compassionate use, the next crucial step will be to formally assess its safety and effectiveness."


'/>"/>

Contact: Donna Ramirez
donna.ramirez@gmail.com
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related biology news :

1. Leading evolutionary scientist to discuss how genome of bacteria has evolved
2. Worlds leading coral experts to gather in Australia
3. Putting plants online: 4 leading botanical gardens to create first online catalog of all plants
4. EMBO welcomes 55 leading life scientists as members
5. Leading statistician receives national citation award
6. Leading childhood asthma group supports federal asthma action plan to reduce disparities
7. BiOptix Participates in Leading Life Sciences Event BioWest 2012
8. Team including UC Riverside entomologist honored for research leading to healthier potato chips
9. Aware Enables Automated Delivery of Radiation Dose Information Through Integration With Leading Radiology Reporting System
10. Discovery of pathway leading to depression reveals new drug targets
11. Leading RSV researcher publishes work at Le Bonheur Childrens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
Breaking Biology Technology: